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Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease with poor survival 
outcome. PAH is classified by the 2009 updated clinical classification of pulmonary hypertension 
and a major subgroup is PAH due to congenital heart disease (CHD) with systemic-to-pulmonary 
shunt. CHD-PAH is a result of systemic-to-pulmonary shunting and chronic increased flow 
that ultimately results in adaptations of pulmonary vasculature and endothelial dysfunction. 
The advanced stage is called Eisenmenger syndrome which forms a small percentage (1%) of 
all CHD patients. Therapies targeted on PAH symptoms are called primary therapy for PAH, 
but most CHD-PAH patients progress to advanced therapy which is directed at the PAH itself. 
In CHD-PAH, advanced therapies are extensively investigated for all three major pathways: 
endothelin-1 receptor antagonists such as bosentan, prostanoids such as epoprostenol and 
phosphodiesterase 5 inhibitors such as sildenafil. Endpoints in most trials were catheterization 
hemodynamics, World Health Organization functional class, six-minute walking distance and 
patient-focused outcomes, based on quality of life questionnaires and Borg dyspnea index. 
The BREATHE-5 and EARLY study were two important randomized controlled trials show-
ing efficacy of bosentan at short follow-up. Moreover in patients with Eisenmenger syndrome, 
one recent survival retrospective study with majority of patients on bosentan showed strong 
survival benefit over conservative therapy. A diversity of prospective cohort and retrospective 
studies were performed but all with limited data, due to small numbers and heterogeneity of 
underlying CHD diagnoses. Further larger studies are needed to determine optimal treatment 
for adults with CHD-PAH. This review focuses on bosentan in CHD-PAH. In particular, we 
discuss outcome of various clinical trials and compare efficacy and safety of bosentan to other 
advanced therapies.
Keywords: pulmonary arterial hypertension, bosentan, endothelin-1 receptor antagonist, 
congenital heart disease
Introduction to the management of pulmonary 
arterial hypertension
Pulmonary arterial hypertension (PAH) is a syndrome characterized by symptoms of 
dyspnea, fatigue, chest pain, and syncope. Underlying mechanism is a progressive 
increase of pulmonary vascular resistance and a sustained elevation of pulmonary arterial 
pressure to more than 25 mmHg at rest.1 It may lead to a decreased functional capacity, 
and right ventricular failure, and is often associated with early death.2,3 PAH can be clas-
sified into five main categories according to the updated clinical   classification of PAH.1 
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2008. This conference revised the Venice classification from 
2003 and evaluated the five main groups. In this review we 
focus on   pulmonary arterial hypertension due to congenital 
heart   disease   (CHD-PAH), which is part of group one. The 
  CHD-PAH group is a well defined population which is inves-
tigated and compared to other groups thoroughly.4–6 New in 
the updated clinical classification of PAH is the   subdivision of 
CHD-PAH in four main groups: 1) Eisenmenger   syndrome; 2) 
PAH associated with systemic-to-pulmonary shunts; 3) PAH 
with small defects; and 4) PAH after corrective   cardiac 
surgery. The pathophysiologic mechanism for all these four 
groups involves intracardiac shunting and increased flow, 
though in different stages. Longstanding increased flow leads 
to pulmonary vascular changes and increased pulmonary 
  vascular resistance. Ultimately this can lead to a reversal 
of the   systemic-to-pulmonary shunt and cyanosis, the so 
called Eisenmenger syndrome classified as group one within 
  CHD-PAH. Eisenmenger syndrome is a multiorgan syndrome 
with symptoms of dyspnea, arrhythmia, congestive heart 
failure, endocarditis, cyanosis, increased blood viscosity, 
iron   deficiency anemia, blood-clotting disturbances and early 
death.7 Patients with Eisenmenger syndrome form a small 
percentage (1%) of the CHD   population.7 An important sub-
group in this Eisenmenger population is patients with Down 
syndrome.8 Once developed Eisenmenger syndrome patients 
tend to remain stable for many years, although highly symp-
tomatic, requiring major lifestyle adjustments due to limited 
  functional capacity.9 Exercise capacity and quality of life 
(QoL) are diminished, pregnancy is strongly contraindicated 
in female patients10 and associated life-threatening complica-
tions are numerous.11 Survival in patients with Eisenmenger 
syndrome is lower than in the general population (55% reach 
50 years of age). Treatment of pulmonary arterial hyperten-
sion is based on the updated clinical classification of PAH. 
Therapies targeted on their symptoms are called primary 
therapy for PAH.12 Unfortunately most   primary therapies 
for category one in the updated classification of PAH are 
not effective to slow down progression. However, primary 
therapies remain applicable for treatment of complications 
as thrombosis, cardiac failure and rhythm disorders. Patients 
with CHD-PAH who progress to functional class II, III, or 
IV , irrespective of anticoagulation, diuretics, digoxin, oxygen 
or lifestyle advices, qualify for advanced therapy. Advanced 
therapy is directed at the underlying mechanism of PAH. 
For PAH treatments with advanced therapy three main 
pathways have been detected: prostacyclin, nitric oxide and 
endothelin-1.13 This resulted in therapies with prostanoids 
such as   epoprostenol,   phosphodiesterase-5   inhibitors such 
as sildenafil and endothelin-1 receptor antagonists such as 
bosentan.12
Bosentan for treatment of patients 
with CHD-PAH
The mechanism of bosentan is a competitive dual inhibition of 
the endothelin-1 receptor.14 Endothelin-1 is a potent vasoconstric-
tor, which also mediates cell proliferation, fibrosis and inflam-
mation.15 Experimental data also showed that   endothelin-1 not 
only modulates vascular smooth muscle tone but also promotes 
cellular proliferation, initiates   cardiac myocyte and nonmyocyte 
hypertrophy. Moreover, endothelin-1 regulates secretion of neu-
rohormonal mediators of cardiac and vascular hypertrophy. It is 
mainly synthesized in endothelial cells and works locally.16 The 
plasma level of endothelin-1 in patients with PAH appeared to be 
elevated, inducing histopathological changes in the pulmonary 
vascular bed.17,18 Endothelin-1 acts on two receptor types, sub-
type A and subtype B. Endothelin-1 receptor subtype A (ETA) 
is predominantly found in smooth muscle cells and fibroblasts. 
Agents which selectively block the type A endothelin-1 receptor 
are ambrisentan and sitaxsentan. Endothelin-1 receptor subtype 
B (ETB) is expressed in smooth muscle and endothelial cells.19 
Activation of endothelial ETB   mediates clearance of endothelin-1 
and vasodilatation by nitric oxide and prostacyclin release.16 
Because of these effects ETB activation is theoretically desirable 
in PAH. Bosentan exhibits a relative ETA to ETB affinity of 20:1 
in vitro assays and is therefore classed a dual endothelin-1 recep-
tor blocker.20 PAH is common in adult patients with congenital 
heart disease21,4 and treatment of CHD-PAH with bosentan is 
extensively investigated.
Efficacy and comparative studies
To determine the efficacy of bosentan for advanced treatment of 
PAH various endpoints have been investigated. The gold standard 
for diagnoses of PAH and evaluation of effect remains cardiac 
catheterization. Most clinical studies performed catheterization. 
However, alternative, less invasive endpoints as the World Health 
Organization functional class, the Borg scale of dyspnea and the 
total distance walked in six minutes (6MWD) were also used 
to examine treatment efficacy.22 The use of the World Health 
Organization modified functional classification (FC) scale 
allows for standardized grading, which is also incorporated into 
treatment guidelines.23 The functional class ranges from class 
I representing PAH without limitation of   physical   activity to 
class IV meaning PAH with inability to carry out any physical 
activity without symptoms. The six-minute walking distance 
(6MWD) is an exercise test with outcome in meters. Benefit 
of the 6MWD is the simplicity, the ease of replication and the Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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possibility of measurements of oxygen saturations at peak 
exercise and its prognostic clinical correlation and prognostic 
significance.24 The validity of the 6MWD is questionable in 
patients with an intellectual disability.25,26 The third noninvasive 
efficacy endpoint is the score on the Borg scale of dyspnea 
with 0 representing no dyspnea and 10 the maximal dyspnea.27 
An overview of efficacy studies in patients with CHD-PAH 
in which the effect of endothelin-1 receptor antagonist was 
investigated is shown in Table 1. The small number of patients 
included in all CHD-PAH studies is worth mentioning as well 
as the heterogeneity of underlying diagnosis.
Randomized controlled trials
In 2001, the first clinical randomized controlled trial on the 
effect of the dual endothelin-receptor antagonist bosentan was 
performed in PAH patients.28 Only patients with idiopathic 
PAH and associated with collagen vascular disease were 
included. For patients with congenital heart disease in total 
two randomized controlled trials (RCT) were conducted. 
The first randomized controlled trial, the BREATHE-5 study 
described bosentan as endothelin-1 receptor antagonist therapy 
in patients with ES.29 This trial also included children (patients 
.12 years) and at baseline all patients were in functional class 
III. The study showed a statistically significant treatment effect 
for reduction of the pulmonary vascular resistance index and 
decrease of the mean pulmonary arterial pressure. Remarkable 
in this trial was the increased pulmonary vascular resistance 
index (PVRi) observed in the placebo arm. This elevation in 
functional class III patients in a small period of time, 16 weeks, 
was not expected. The 6MWD resulted in a treatment effect of 
53 m (P = 0.008). Directly after the end of this study, a sub-
group was included in an extension prospective cohort study. 
This 6MWD data showed improvement in those patients who 
had initially received placebo (33 m) and maintenance of the 
effect in patients who were treated with bosentan (67 m).30
The second randomized controlled trial investigating 
bosentan was the EARLY study by Galiè et al about bosentan 
treatment exclusively of PAH patients in functional class II.31 
A subgroup (n = 32) were patients with   CHD-PAH. Change 
in 6MWD was not statistically significant at 6 months from 
baseline, though the 6MWD was increased in the endothelin-1 
receptor antagonist group and decreased in the placebo group. 
Bosentan treatment was associated with a lower incidence of 
decline in functional class compared to placebo (P = 0.03).
Long-term follow-up and survival
Since approval of the European Medicines Agency (EMEA) 
and the Food and Drug Administration (FDA) for   bosentan, 
four long-term trials have been conducted (follow-up 
12–28 months). D’ Alto et al described a 12 months safety 
and efficacy study in ES patients and showed a significant 
reduction of the pulmonary vascular resistance index (PVRi) 
and systemic vascular resistance index (SVRi) ratio.32 This 
Table 1 PAH studies reporting effect of bosentan in patients with CHD-PAH
First author Design  Year n  F/U 
(months)
Endpoint Adverse effect
Galiè (BReATHe-5) RCT 2006 54 4 Functional class; catheterization Le; headache; 
dizziness;  
palpitations
Apostolopoulou Prospective cohort 2007 21 28 Treadmill Dizziness; flushing;  
hemoptysis
D’Alto Prospective cohort 2007 22 12 6MwD; catheterization Leg edema, LFT .  
3UNL
Diller Retrospective cohort 2007 18 24 6MwD Death
Galiè (eARLY) RCT 2008 32 6.5 6MwD; catheterization Anemia, cardiac  
failure
Gatzoulis Prospective cohort 2008 37 10 6MwD Le; diarrhea; headache;   
AP; abortion
Berger Post-hoc 2009 54 4 Catheterization Angina pectoris
Diaz (BReATHe-5) Prospective cohort 2009 10 25 6MwD None
Duffels Retrospective cohort 2009 58 22 Laboratory tests; 6MwD; MRi Throat pain; LFT .  
3UNL; death
Dimopoulos Retrospective cohort 2010 50 48 Survival –
Jing Multicenter open-label  
trial
2010 34 6 6MwD; catheterization –
Abbreviations: F/U, follow-up; PAH, pulmonary arterial hypertension; RCT, randomized controlled trials; 6MwD, 6 minute walking distance; MRi, magnetic resonance 
imaging; Gi, gastrointestinal; Le, leg edema; AP, angina pectoris; LFT, liver function test; UNL, upper normal limits.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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suggests a greater effect of endothelin-1 receptor antagonists 
on pulmonary rather than on systemic circulation. Bosentan 
increased the pulmonary and systemic flow significantly. The 
pulmonary and systemic pressures decreased although not 
significantly. Bosentan treatment caused a greater reduction 
in right ventricular than in the left ventricular after-load after 
one-year follow-up, resulting in a reduction of right-to-left 
shunting, an improvement in pulmonary blood flow, and 
ultimately, in systemic oxygen delivery.
The second long-term study was performed by Diller et al 
looking at 18 (14 females) patients with median follow-up of 
29 months.33 In total 15 patients had Eisenmenger syndrome. 
At baseline all patients were in functional class III. Compared 
to baseline the arterial saturation increased within the first six 
months of treatment (81.1 ± 4.9% vs 84.7 ± 2.6%, P = 0.014). 
6MWD improved significantly in 0–6 months, 6–12 months 
and 1–2 years of treatment (P = 0.005).   Functional class also 
improved during follow-up (P = 0.001). Two long-term studies 
that showed a short-term efficacy followed by gradual return to 
baseline were performed by Apostolopoulou et al and Duffels 
et al.26,34 The first study showing   stabilization was by Apostolo-
poulou et al with two year follow-up using   treadmill exercise 
testing, using an exercise protocol described Northridge et al.35 
Most patients (68%) were   cyanotic and all patients had severe 
right ventricular   dilatation and hypertrophy on echocardiogra-
phy. After the initial improvement at 16 weeks of treatment in 
maximal and submaximal exercise, all exercise parameters at 
two years seem to be slowly returning to baseline. Next study 
was by Duffels et al who have done a subgroup analysis after 
two years follow-up on bosentan efficacy in CHD-PAH, com-
paring patients with and without Down syndrome.26 Although 
not significant, a trend towards improvement was seen in 
patients with Eisenmenger syndrome. This   treatment effect in 
both studies is different from the observation by D’Alto et al 
and Diller et al.32,33 The discrepancy between the first two stud-
ies and the other two CHD-PAH trials may be due to a higher 
cardiac output with lower pulmonary   vascular   resistance of 
their population, possibly indicating less advanced disease 
stage or natural progression.
In contrast, a strong survival benefit was shown in one recent 
retrospective study performed in patients with   Eisenmenger 
syndrome on various advanced therapies (AT) with   majority 
of patients on bosentan (73.5%, n = 50).9 These patients were 
compared to 168 patients with Eisenmenger syndrome not on 
AT, showing a strong survival benefit for advanced therapies. 
In absolute numbers two (2.9%) patients on AT died versus 50 
(29.8%) not on AT. In this survival study Eisenmenger syndrome 
patients who received advanced therapy were likely to be at the 
worst end of the spectrum and therefore at a higher risk of death. 
In accordance with this, patients on advanced therapy in the 
study were significantly older, were more exercise impaired, and 
were more likely to receive anticoagulants and to have a history 
of syncopal episodes, indicating overall a more advanced disease 
stage.   Furthermore, another recent meta-analysis demonstrated 
improved survival with targeted therapy resulting in a number 
of 20 needed treatment to prevent one death at 1 year.36
Finally, one study investigated the short-term and 
  long-term effect of bosentan on systemic-to-pulmonary shunts 
in adults compared to children.37 This study showed short-term 
improvement in both adults and children with PAH but at long-
term follow-up a progressive decline in   beneficial bosentan 
effect was observed. The decline appeared most pronounced 
in the pediatric patients, who, in that study, tended to have 
more severe disease at baseline.
Retrospective and prospective  
cohort studies
Besides the randomized controlled trials and long-term studies, 
several prospective cohort, one post hoc analysis and multiple 
retrospective studies were performed. The post hoc subgroup 
analysis of the BREATHE-5 study by Berger et al compared 
atrial septal defects versus ventricular septal defects.11 The 
group of ventricular septal defects included patients with an 
isolated ventricular septal defect and patients with an atrial 
septal defect combined with a ventricular septal defect. Inter-
estingly, an increased pulmonary vascular resistance index 
(PVRi) appeared more in placebo-treated ASD patients and 
an opposite decrease in PVRi was more observed in the VSD 
bosentan-treated patients. The analysis showed that the effect 
of bosentan treatment was similar in ES patients with ASDs 
and patients with VSDs, indicating that the location of septal 
defect may have little bearing in relation to the tricuspid valve. 
Results of the BREATHE-5 prospective cohort extension study 
with two cohorts, ex-placebo patients and ex-bosentan patients, 
showed longer 6MWD and less deterioration of functional 
class for the ex-bosentan group.30 The study by Jing et al per-
formed cardiac catheterization after 12 weeks follow-up and 
included 34 (37%) patients with CHD-PAH.38 For the total 
cohort, including CHD-PAH patients, the increase in cardiac 
output agrees with the results of two previous studies, whereas 
Duffels observed no change in cardiac output response to 6 
months of treatment with bosentan.39
Safety and tolerability
In addition to efficacy, the clinical studies mentioned above 
investigated the safety and tolerability of endothelin-1 receptor Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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antagonist treatment. An overview of adverse effects in those 
studies with CHD-PAH is shown in Table 1. Relative contrain-
dications to initiate bosentan treatment are moderate to severe 
hepatic impairment because the metabolism of bosentan occurs 
by cytochrome P450 CYP2C9 and CYP3A4.20
Severe adverse events
In the BREATHE-5 study, severe adverse events were more 
frequently seen in bosentan-treated patients than in the pla-
cebo group: palpitations (11% versus 0%) and chest pain (8% 
versus 0%). In the BREATHE-5 prospective cohort extension 
study, four patients (11%) experienced a total of seven serious 
adverse events (palpitations, viral gastroenteritis, increased 
liver function test (LFT), lethargy, nausea and chest pain 
(11%).30 The report of spontaneous abortion in BREATHE-5 
open-label extension (OLE) highlights the importance of 
the use of effective contraception. D’Alto et al reported one 
patient with nonsustained ventricular tachycardia. Debates 
about enhanced hypoxemia induced by endothelin-1 recep-
tor antagonists in patients with PAH due to congenital heart 
disease have been rejected by the described studies. Initially, 
concerns were raised about the effect of endothelin-1 receptor 
antagonists on the potentially more reactive systemic circu-
lation compared to the obstructed pulmonary vascular bed, 
which could hypothetically result in worsening of systemic 
hypoxemia (as a result of increased right-to-left shunting). 
However, no such effect occurred.
In the survival analysis of Eisenmenger syndrome patients 
by Dimopoulos et al, 52 patients died during a median 
follow-up of 4.0 years.9 Only two of them died while on 
advanced therapy but what is unclear is whether they were 
on bosentan or other advanced therapy.
Liver function test disturbances
A potential major complication is disturbance of the liver 
function tests (LFT). In the long-term trials, D’Alto et al 
reported three patients with a four times elevation of liver 
function tests at two months of follow-up. Bosentan was 
reduced from 125 mg twice a day to 62.5 mg twice a day 
with a complete normalization of the aminotransferase 
level.32 In the other two studies with a long-term follow-up 
no significant rises in liver transaminases were reported.33,34 
Furthermore, the induction of hepatic enzymes can make 
hormonal contraception unreliable. To conclude, amino-
transaminases levels of more than three times upper normal 
limits need further evaluation. Discontinuation of bosentan 
is recommended when levels are more than five times UNL, 
and reintroduction can only be considered if levels were less 
than eight times upper normal limits. In all studies, liver 
function tests normalized after dose reduction. Other labora-
tory tests were often not described in the studies mentioned 
above. However, a decrease in hemoglobin (,10 g/dL) was 
seen in one patient (3%) in the study of D’Alto et al and in 
the BREATHE-5 study.30 Monitoring of the international 
normalized ratio in the study of Apostolopoulou did not 
show interference.34
Mild adverse effects
Various mild adverse events were reported eg, edema, 
hypersensitivity, rash and reversible thrombocytopenia.40 
Clinical studies (not focusing) on CHD-PAH showed inci-
dences of leg edema between 10% reported by Channick 
et al41 and 27% in BREATHE-2.42 In the BREATHE-5 
study, leg edema was more frequently reported in the 
bosentan-treated patients compared to the placebo group 
(19% vs 12%). Moreover, headache (14% versus 12%) and 
dizziness (8%   versus 6%) were more common in bosentan-
treated patients.29 In the EARLY study the most commonly 
reported mild adverse event in the bosentan group was 
nasopharyngitis.31 The incidence of leg edema was simi-
lar in the two groups. BREATHE-5 OLE showed fatigue, 
dizziness, and   headache (each 5%), leg edema (19%); 
nasopharyngitis (11%);   diarrhea (8%).30 The mechanism 
of edema is not entirely clear. Alternatively it may be the 
result of vasodilatation caused by bosentan, or dysfunction 
of renal tubular function.16 In the 28 months follow-up study 
of Apostolopoulou et al only flushing and dizziness were 
reported which resolved within two weeks without regimen 
changes.34 In all but one study, hypotension or syncope did 
not appear. Only the BREATHE-5 reported one episode 
of vasovagal   syncope.29 Additionally, none of the studies 
reported an increase in cyanosis after long-term treatment 
with endothelin-1   receptor antagonist (28 months).34
Patient-focused outcomes
Patient focused assessments in clinical CHD-PAH studies 
are important due to possible discrepancies between clini-
cal performance and objective exercise capacity of patients. 
PAH patients are likely to adapt to decreased needs. In the 
literature, several scores are developed to measure perception 
of improvement in CHD-PAH.15,43 The quality of life (QoL) 
scores and the Borg dyspnea index are most frequently used. 
Unfortunately, the CHD-PAH trials did not consistently use 
one type of scoring system.15
The QoL evaluation was usually performed using the 
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ing with PAH questionnaire.43 The SF-36 is a well-documented, 
widely used and validated, self-  administered QoL scoring 
system incorporating 36 questions.26 The SF-36 includes 
eight independent scales (scored as 0–100) that assesses the 
general health concepts of Physical Functioning, limitations 
caused by physical health problems (Role – Physical), Body 
Pain, General Health Perceptions, Vitality, Social Functioning, 
limitations caused by emotional problems (Role – Emotional), 
and Mental Health. The SF-36 was used by Duffels et al in 
the description of exercise capacity and quality of life in 
adults with CHD-PAH with and without Down syndrome.26 
In EARLY study, the SF-36 scores showed that 57% of 
bosentan-treated patients and 38% of placebo-treated patients 
had experienced improved clinical performance (P , 0.05).31 
The study reported significantly improvement of QoL in 2 
of 8 SF-36 scales in patients without Down syndrome. The 
Minnesota living with PAH questionnaire measures patients’ 
perceptions on physical, socioeconomic, and psychological 
aspects of daily life in relation with their CHD.26 Scores for 
the total Minnesota questionnaire ranged from 0–105, with 
higher scores reflecting worse perceived QoL. Duffels et al 
reported no changes in mean questionnaire scores comparing 
patients with and without Down syndrome (33, range 6–67; 
and 38, range 0–67; P = 0.7).
The Borg dyspnea index was only used in a few trials.31,32,44 This 
scoring system is a visual analog score which attempts to quantify 
effort during the 6MWD.15 A fall in score means less exertional 
breathlessness. D’Alto et al described a   reduction in the Borg index 
(5.3 vs 6.5; P , 0.001) after 12 months follow-up.32 Apostolopou-
lou et al reported a decline of Borg dyspnea index by 0.8 points, 
reaching baseline values at 2 years follow-up.34
Combination of therapies
With multiple advanced therapies for PAH acting on three 
different pathways a logical step forward in treatment of PAH 
was to look at the combination agents.15 Most evidence was 
gained for the efficacy of bosentan as monotherapy and the 
combination of the endothelin-1 receptor antagonist with 
another oral advanced therapy is becoming increasingly com-
monplace.45 For the combination of therapies the   goal-oriented 
approach is a recommended strategy.46 This goal-oriented 
approach in patients with severe PAH focuses on combinations 
of endothelin-1 receptor antagonists, sildenafil and inhaled 
iloprost to achieve acceptable long-term results. Moreover 
the goal-oriented therapy reduces the need for intravenous 
prostaglandin treatment and lung transplantation.46 Safety 
investigation of combination therapy was performed in healthy 
subjects by Burgess et al.47 This study reported interaction 
for coadministration of bosentan 125 mg twice daily with 
sildenafil 80 mg three times daily; this resulted in a 50% rise 
in bosentan levels and fall in sildenafil by nearly two thirds. 
Moreover one report (not placebo-controlled) looking at the 
combination of bosentan and sildenafil showed no greater 
number of liver enzyme elevations compared to endothelin-1 
receptor antagonist monotherapy.46
Conclusions
The rationale for treatment is clear, given the progressive 
character of the disease. Clinical recommendations are found 
in several guidelines described by the European Society of 
Cardiology and the American College of Cardiology.48,49 
Regarding effectiveness in the presented studies, bosentan 
treatment has shown to improve short-term exercise tolerance 
in patients with CHD-PAH in functional class II, III and IV .31 
The data for long-term follow-up remains conflicting because 
two long-term trials showed beneficial effect and two trials 
reported initial efficacy followed by gradual return to base-
line. Only limited data is available for specific diseases or 
subgroups in CHD-PAH. The BREATHE-5 study showed 
patients with functional class III Eisenmenger syndrome 
to deteriorate when they were placebo-treated in contrast 
to bosentan-treated patients who improved significantly.29 
Conclusion for Eisenmenger syndrome patients is that 
bosentan treatment could be considered irrespective of 
the nature of the septal defect.11 Finally, larger studies are 
needed to determine optimum treatment strategy for adults 
with   CHD-PAH due to systemic-to-pulmonary shunt. The 
application of endothelin-1 receptor antagonist like bosentan 
(and other advanced therapies) in Eisenmenger syndrome 
seems to be beneficial and treatment with bosentan is a proper 
consideration. Systematic cohort studies and ultimately new 
placebo-controlled trials are desired to assess the effects 
on survival to examine the effect of bosentan on long-term 
survival. In conclusion, bosentan seems to offer benefit to 
those patients with CHD-PAH in moderate to severe cases 
(Eisenmenger patients), but the incidence of adverse events 
require close monitoring by clinicians.
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